Compare PESI & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | SABS |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | 307 | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.3M | 344.8M |
| IPO Year | 1996 | 2020 |
| Metric | PESI | SABS |
|---|---|---|
| Price | $17.46 | $3.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | ★ 267.6K | 260.5K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.61 | ★ 78.53 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $642,000.00 | N/A |
| Revenue This Year | $34.62 | N/A |
| Revenue Next Year | $77.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.58 | $1.85 |
| 52 Week High | $21.32 | $5.15 |
| Indicator | PESI | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 45.42 |
| Support Level | $14.18 | $3.39 |
| Resistance Level | $19.02 | $4.02 |
| Average True Range (ATR) | 0.76 | 0.12 |
| MACD | -0.17 | -0.02 |
| Stochastic Oscillator | 5.18 | 44.79 |
Perma-Fix Environmental Services Inc is a nuclear services company and provider of nuclear and mixed waste management services. The company's nuclear waste services include treatment and management of radioactive and mixed waste (waste containing both hazardous and low-level radioactive waste). The company operates through two segments: i) The treatment segment: It offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and ii) the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.